Pfotenhauerstrasse 108
Cenix BioScience GmbH
Cenix is equipped to do high-throughput, genome-scale RNAi screening. The firm believes that its infrastructure and expertise will allow it to help Big pharma and biotech partners sort through masses of targets to find those with biological relevance. Management believes its methodology can also contribute to drug development--RNAi could, for instance, act as a modifier in screening assays, to see whether this additional means of silencing a gene could improve a drug candidate's activity.
More from Strategy
More from Business
• By
The companies will co-develop the drug for additional indications beyond Huntington’s disease, while Prilenia retains rights in key global markets.
• By
Funding cuts at the National Institutes of Health, big pharma’s US onshoring moves, GCC partnerships and talks with the Indian government to solve intellectual property challenges are discussed in an interview with Aragen’s CEO, who is also keenly watching the Trump administration’s moves on pharma tariffs
• By
Amgen announces major expansion of existing US site amid ongoing threat of pharma import tariffs.